Study identifies benefits, risks linked to popular GLP-1 weight-loss drugs
GLP-1 medications tied to decreased risk of dementia, addiction; increased risk of kidney, pancreas and gastrointestinal problems Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease